Drug intelligence / Profile preview

Subgam

Development stage: Phase 3
Lead developer: Bio Products Laboratory
Administration: Subcutaneous

Overview

Subgam is a human normal immunoglobulin solution used for the treatment of primary immunodeficiency diseases (PID). It is administered subcutaneously and provides passive immunity by increasing IgG levels in the body. Subgam is produced from the plasma of human donors and contains IgG subclasses IgG1, IgG2, IgG3, and IgG4. It is not licensed for prophylactic use against hepatitis A, measles, or rubella, though it may be used for hepatitis A prophylaxis at higher doses.

Brand names: Subgam
Other names: Human normal immunoglobulinSubcutaneous immunoglobulinSCIG

Beyond the preview

Go deeper on Subgam.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Subgam.

Explore the full profile